Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02735980 · ClinicalTrials.gov registry record · Phase 2
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
A Phase 2 study of Small-cell Lung Cancer, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
- 20
- Study locations
NCT02735980 is a Phase 2 study of Small-cell Lung Cancer that has completed, run by Eli Lilly and Company. The registered enrollment target is 133 participants, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT02735980, a Phase 2 study of Small-cell Lung Cancer, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will evaluate how the body processes the drug and how the drug affects the body. The study will also evaluate the association between tumor response and the participant's perceived quality of life.
Conditions Studied
Interventions
- DRUG Prexasertib
Study Locations (20)
Other
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Besançon
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Lille
- "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician." - Montpellier
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Vantoux
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Halle
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Athens
Tennessee
- Chattanooga Oncology Hematology Associates - Chattanooga
- Sarah Cannon Cancer Center - Nashville
- Tennessee Oncology PLLC - Nashville
- Vanderbilt University Medical Center - Nashville
Florida
- Florida Cancer Specialists - Fort Myers
- Florida Cancer Specialists and Research Institute - St. Petersburg
Texas
- The Center for Cancer and Blood Disorders - Fort Worth
- University of Texas MD Anderson Cancer Center - Houston
Arkansas
- Highlands Oncology Group - Fayetteville
Connecticut
- Yale University School of Medicine - New Haven
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Massachusetts
- Massachusetts General Hospital - Danvers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2016-05-11 |
| Est. Completion | 2019-02-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02735980
The ClinicalTrials.gov registry entry for NCT02735980 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 230-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (42% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Prexasertib is the first listed.
NCT02735980 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Tennessee, Florida.
Frequently Asked Questions
What is clinical trial NCT02735980 about?
NCT02735980 is a clinical study titled "A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer". The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will evaluate how the body processes the drug and how the drug affects the body. The study will also evaluate the associ...
What is the current status of trial NCT02735980?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2016-05-11. Estimated completion is 2019-02-12.
What conditions does trial NCT02735980 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT02735980?
The interventions under investigation include: Prexasertib (DRUG).
Who is sponsoring clinical trial NCT02735980?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02735980 being conducted?
This trial has 20 study locations across Arkansas, Connecticut, District of Columbia, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
RECRUITING · Phase 2
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
Study of Trilaciclib and Lurbinectidin
RECRUITING · Phase 2
-
Phase 2 Study of Fingolimod in Lung Cancers
RECRUITING · Phase 2
-
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
-
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.